Otolaryngology Online Journal

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44 151 808 1136

Rapid Communication - Otolaryngology Online Journal (2024) Volume 13, Issue 7

Treatment Approaches for Oropharyngeal Cancer: Surgery, Radiation, and Immunotherapy

Momoko Reischl *

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University of Brescia, Italy

*Corresponding Author:
Momoko Reischl
Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University of Brescia, Italy
E-mail: reischlmomoko@unibs.it

Received: 29-Dec-2023, Manuscript No. JORL-23- 123742; Editor assigned: 01-Jan-2024, PreQC No. JORL-23- 123742; Reviewed:15-Jan-2024, QC No. JORL-23- 123742; Revised:20-Jan-2024, Manuscript No. JORL-23- 123742 (R); Published:27-Jan-2024, DOI:10.35841/ jorl-13.7.364

Visit for more related articles at Otolaryngology Online Journal

Introduction

Surgery is a primary treatment for oropharyngeal cancer, aiming to remove the tumor and affected tissues while preserving vital functions such as speech and swallowing. Techniques range from minimally invasive procedures to extensive operations like neck dissections, tailored based on the tumor's size, location, and staging [1].

High-energy radiation targets and destroys cancer cells. Radiation therapy, often employed as the primary treatment or in combination with surgery, aims to eradicate remaining cancer cells while minimizing damage to surrounding healthy tissues [2].

Chemotherapy utilizes drugs to kill cancer cells and is often used concurrently with radiation therapy or surgery. It may be recommended based on the cancer's stage, spreading patterns, and the patient's overall health [3].

Targeted therapies focus on specific abnormalities within cancer cells, disrupting their growth and survival. This approach minimizes damage to healthy cells and often results in fewer side effects compared to traditional chemotherapy [4].

Immunotherapy has emerged as a promising treatment option for oropharyngeal cancer. It stimulates the patient's immune system to recognize and destroy cancer cells. Immune checkpoint inhibitors, a type of immunotherapy, have shown efficacy in some cases [5].

Treatment strategies often involve combinations of surgery, radiation, chemotherapy, and immunotherapy. This multimodal approach aims to enhance treatment efficacy by targeting cancer cells through different mechanisms [6].

Following treatment, rehabilitation plays a crucial role in restoring functions like speech and swallowing. Supportive care, including nutritional support and addressing potential side effects, is essential for a patient's overall well-being [7].

Advancements in surgical techniques, including robotic-assisted surgery, have enabled more precise tumor removal while minimizing damage to surrounding healthy tissues. This enhances recovery and reduces post-operative complications [8].

Innovations in radiation therapy, such as intensity-modulated radiation therapy (IMRT) and proton therapy, allow for more targeted and precise delivery of radiation, minimizing damage to healthy tissues [9].

Ongoing clinical trials explore novel therapies, new drug combinations, and advancements in treatment techniques for oropharyngeal cancer. Participation in these trials offers potential access to cutting-edge treatments and contributes to advancing medical knowledge [10].

conclusion

Treatment approaches for oropharyngeal cancer have seen significant advancements, offering a range of options that can be tailored to individual patients. The multidisciplinary nature of treatment, incorporating surgery, radiation therapy, chemotherapy, targeted drug therapy, and immunotherapy, provides a comprehensive arsenal against this type of cancer. Continued research, technological innovations, and the integration of multimodal treatment strategies hold promise for improved outcomes, reduced side effects, and enhanced quality of life for individuals battling oropharyngeal cancer. Collaborative efforts between healthcare professionals, ongoing clinical trials, and a patient-centered approach remain integral in shaping the landscape of treatment and fostering hope for better prognoses in the future.

References

  1. Mesia R, Iglesias L, Lambea J, et al. SEOM clinical guidelines for the treatment of head and neck cancer (2020). Clinical and Translational Oncology. 2021;23:913-21.
  2. Indexed at, Google Scholar, Cross Ref

  3. Lin TA, Garden AS, Elhalawani H, et al. Radiographic retropharyngeal lymph node involvement in HPV?associated oropharyngeal carcinoma: patterns of involvement and impact on patient outcomes. Cancer. 2019;125(9):1536-46.
  4. Indexed at, Google Scholar, Cross Ref

  5. Wang H, Zhao Q, Zhang Y, et al. Immunotherapy advances in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma and its relationship with human papillomavirus. Frontiers in immunology. 2021;12:652054.
  6. Indexed at, Google Scholar, Cross Ref

  7. Deschuymer S, Mehanna H, Nuyts S. Toxicity reduction in the treatment of HPV positive oropharyngeal cancer: emerging combined modality approaches. Frontiers in Oncology. 2018;8:439.
  8. Indexed at, Google Scholar, Cross Ref

  9. Szturz P, Nevens D, Vermorken JB. Oligometastatic disease management: finding the sweet spot. Frontiers in Oncology. 2020;10:617793.
  10. Indexed at, Google Scholar, Cross Ref

  11. Bossi P, Alfieri S, Strojan P, et al. Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: a review of the literature. Critical reviews in oncology/hematology. 2019;137:84-91.
  12. Indexed at, Google Scholar, Cross Ref

  13. Saba NF, Pamulapati S, Patel B, et al. Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer. Cancers. 2023;15(7):1959.
  14. Indexed at, Google Scholar, Cross Ref

  15. Wu SY, Yom SS. Current standards for organ preservation in locoregionally advanced non-nasopharyngeal head and neck cancer and evolving strategies for favorable-Risk and platinum-Ineligible populations. Current treatment options in oncology. 2019;20:1-4.
  16. Indexed at, Google Scholar, Cross Ref

  17. Rossillon A, Benhamou J, Baccar LS, et al. Astonishing Evolution in Oropharyngeal Cancer with Immunotherapy: A Case Report. Cancer Investigation. 2019;37(10):531-4.
  18. Indexed at, Google Scholar, Cross Ref

  19. Inukai D, Kan T, Yamanaka S, et al. Pathological and virological studies of p16-positive oropharyngeal carcinoma with a good response to neoadjuvant chemotherapy. Microorganisms. 2020;8(10):1497.
  20. Indexed at, Google Scholar, Cross Ref

Get the App